Abeona Therapeutics (ABEO) CFO has shares withheld to cover taxes

Q: What insider transaction did Abeona Therapeutics (ABEO) CFO Joseph Walter Vazzano report?

Joseph Walter Vazzano reported 1,478 shares of Abeona Therapeutics common stock being withheld at $6.53 per share to satisfy tax obligations upon vesting of restricted stock awards. This reflects a tax-related share disposition, not a discretionary purchase.

Q: How many Abeona Therapeutics (ABEO) shares does the CFO hold after this transaction?

After the tax withholding, the CFO directly holds 492,079 shares of Abeona Therapeutics common stock. This figure represents his reported direct ownership position following the 1,478-share withholding on July 21, 2026.

Q: Was the Abeona (ABEO) CFO’s July 21, 2026 transaction an open-market sale?

The transaction is described as shares withheld to satisfy tax withholding obligations upon restricted stock vesting. This indicates a tax withholding event with shares withheld by the issuer, rather than a discretionary open-market sale by the CFO.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Vazzano Joseph Walter reported reported sale transactions in this Form 4 filing.

Abeona Therapeutics Chief Financial Officer Joseph Walter Vazzano reported that 1,478 shares of common stock were withheld at $6.53 per share to satisfy tax withholding obligations upon vesting of restricted stock awards. After this tax-related withholding, he directly holds 492,079 shares.

Insider Trade Summary

Net Seller: 1,478 shares

Net Sell 1 txn

Insider Vazzano Joseph Walter

Role Chief Financial Officer

Sold 1,478 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	1,478	$6.53	$10K

Holdings After Transaction: Common Stock — 492,079 shares (Direct)

Footnotes (1)

F1. Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards.

Key Figures

Shares withheld for taxes: 1,478 shares Per-share value: $6.53 per share Shares held after transaction: 492,079 shares

3 metrics

Shares withheld for taxes 1,478 shares Withheld to satisfy tax obligations upon vesting on July 21, 2026

Per-share value $6.53 per share Implied value of the 1,478 shares withheld for tax obligations

Shares held after transaction 492,079 shares Direct common stock ownership following the tax-related withholding

Key Terms

restricted stock awards, tax withholding obligations, Chief Financial Officer

3 terms

restricted stock awards financial

"upon vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

tax withholding obligations financial

"shares withheld to satisfy tax withholding obligations"

Chief Financial Officer financial

"reporting person’s title is Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 04:31 PM Accepted by SEC EDGAR 07/22/2026 - 04:30 PM

FAQ

What insider transaction did Abeona Therapeutics (ABEO) CFO Joseph Walter Vazzano report?

Joseph Walter Vazzano reported 1,478 shares of Abeona Therapeutics common stock being withheld at $6.53 per share to satisfy tax obligations upon vesting of restricted stock awards. This reflects a tax-related share disposition, not a discretionary purchase.

How many Abeona Therapeutics (ABEO) shares does the CFO hold after this transaction?

After the tax withholding, the CFO directly holds 492,079 shares of Abeona Therapeutics common stock. This figure represents his reported direct ownership position following the 1,478-share withholding on July 21, 2026.

Was the Abeona (ABEO) CFO’s July 21, 2026 transaction an open-market sale?

The transaction is described as shares withheld to satisfy tax withholding obligations upon restricted stock vesting. This indicates a tax withholding event with shares withheld by the issuer, rather than a discretionary open-market sale by the CFO.

At what price were the Abeona Therapeutics (ABEO) shares valued for the CFO’s tax withholding?

The 1,478 shares associated with the tax withholding event were valued at $6.53 per share. This per-share value is used to quantify the disposition tied to the vesting of restricted stock awards.

Was the Abeona Therapeutics (ABEO) CFO’s transaction made under a Rule 10b5-1 trading plan?

No. The Rule 10b5-1 checkbox for the reported transaction was not marked as plan-based, indicating it was not reported as executed pursuant to a Rule 10b5-1 trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazzano Joseph Walter

(Last)

(First)

(Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND

OHIO

44103

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/21/2026		S⁽¹⁾		1,478	D	$6.53	492,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards.

	/s/ Joseph Vazzano	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR